Bioequivalence of narrow therapeutic index drugs and immunosuppressives

Brian Godman*, Christoph Baumgärtel

*Corresponding author for this work

Research output: Contribution to journalComment/debate

4 Citations (Scopus)


Stricter bioequivalence criteria are in place for generics where there are narrow therapeutic indexes such as generic immunosuppressives, enhancing their acceptance despite limited published studies. No serious issues have been reported to date with generic ciclosporin despite being on the market in Europe for more than 10 years.

Original languageEnglish
Pages (from-to)159-160
Number of pages2
JournalGaBI Journal
Issue number4
Publication statusPublished - 2015
Externally publishedYes


  • Bioequivalence
  • Ciclosporin
  • EMA
  • Generics
  • Immunosuoppressives
  • Narrow therapeutic index drugs


Dive into the research topics of 'Bioequivalence of narrow therapeutic index drugs and immunosuppressives'. Together they form a unique fingerprint.

Cite this